On Oct 20, 2025, Oncolytics Biotech Inc. announced it filed a registration statement on Form F‑4 with the SEC, including a preliminary management circular/prospectus, to facilitate a special meeting of shareholders that will vote on a series of transactions to change the company’s jurisdiction of incorporation from Alberta, Canada to the State of Nevada, USA.
The filing outlines a two‑step process: a continuance from Alberta to British Columbia, followed by domestication to Nevada, expected to take effect on January 1, 2026, or as soon as practicable thereafter. The company states that the change will reduce regulatory burden and operating costs, and enable more efficient capital raising.
The special meeting will require a two‑thirds majority vote of shareholders by proxy or in person. The company also proposes a new incentive award plan at the same meeting. No material changes to operations or financial results are anticipated as a result of the continuance or domestication, and the company’s common equity will continue to trade on Nasdaq under the ticker ONCY.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.